Intermittent fasting and a no-sugar diet for Long COVID symptoms: a randomized crossover trial
Bunker T, Horne BD, Baldwin MD, Sorrells R, Turner S, Laube L, Solomon A, Horne LA, Novack J
Scientific reports · 3 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2025-07-29 · Sci Rep · vol. 15 · número 1 · pág. 27563
- Editorial
- Nature Portfolio
- Citado
- 5 citas · más que el 90% de estudios similares · 2.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 61 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC-ND
- Áreas de investigación
- Dietary Effects on Health · Long-Term Effects of COVID-19 · Diet and metabolism studies
- Palabras clave
- long COVID, intermittent fasting, time-restricted eating, dietary intervention, symptom severity, patient-reported outcomes, fasting safety
- MeSH
- humans, treatment outcome, fasting, cross-over studies, adult, aged, middle aged, female, male, covid-19, sars-cov-2, intermittent fasting
9 autores
- Thomas Bunker · autor de correspondencia
- Benjamin Davies Horne🇺🇸Intermountain Medical Center; Stanford Medicine; Stanford University
- Mark D. Baldwin🇺🇸Arkansas Colleges of Health Education
- Robert Sorrells🇺🇸Pacific Northwest University of Health Sciences
- Sabrina Turner🇺🇸University of Nebraska Medical Center
- Laynee Laube🇺🇸University of Washington
- Ari Solomon
- Lucy A. Horne🇺🇸Utah State University
- Jeffrey P. Novack🇺🇸 · autor de correspondenciaPacific Northwest University of Health Sciences; Arkansas Colleges of Health Education
Resumen
El texto original del estudio, en el idioma en que se publicó.
Long COVID (LC) is a common chronic health condition that impairs daily functioning and social connections. This is the first randomized clinical trial to directly compare the effect of two Intermittent Fasting regimens on LC symptoms. The main objectives of this 10-week randomized cross-over trial are to compare the efficacy and safety of 4 weeks of 1-2 day fasting plus a restricted diet vs 4 weeks of mild time-restricted eating (TRE) and a restricted diet in reducing patient-reported LC symptoms. After a 2-week run-in, subjects were randomized to treatment A (TRE) or treatment B (Fasting) for 4 weeks. Subjects then crossed over to the other treatment for 4 weeks. The median fasting duration was 38 h (night-day-night), and the mean duration was 42 h. Symptoms were assessed via weekly online surveys. Primary outcomes were changes in LC symptom severity scores (LC-Scores) and in the number of LC symptoms (numLCsym) between treatments. Secondary outcomes were changes in LC-Scores and numLCsym over the 10-week trial. Fasting was superior to TRE alone in reducing LC-Scores (p = 0.008). The numLCsym decreased - 5.0 during the Fasting 4 weeks vs - 1.4 in the TRE 4 weeks (p = 0.002). Altogether, the 10-week regimen of a no-sugar diet, TRE and Fasting decreased the mean LC-Score by 51.8% (p < 0.0001) from 37.8 to 18.2. Similarly, numLCsym decreased from 20.5 to 12.2, a decrease of 40.6% (p < 0.0001). No major adverse safety events were recorded. Both intermittent fasting interventions decreased symptoms over the 10-week trial but the more intense fasting regimen was significantly better.Trial registration: ClinicalTrials.gov Identifier NCT06214455.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.